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Abstract
Background—There is debate about how best to measure patient reported outcomes (PROs) in
irritable bowel syndrome (IBS). We pooled data from clinical trials to measure the psychometric
properties of IBS endpoints, including binary responses (e.g. “adequate relief”) and 50%
improvement in symptom severity.
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Methods—We pooled patient-level data from 12 IBS drug trials involving 10,066 participants. We
tested the properties of binary response and 50% improvement endpoints, including the impact of
baseline severity on performance, and measured construct validity using clinical anchors. We
calculated confidence intervals for the psychometric parameters of each endpoint, and compared
estimates side-by-side between PROs.
Results—There were 9044 evaluable subjects (age=44; 85% F; 58% IBS-C; 31% IBS-D). Using
the binary endpoint, the proportion responding in the mild, moderate, and severe groups was 42%,
40%, and 38%, respectively (p=0.0008). There was no effect of baseline severity on binary response
(OR=0.99; CI=0.99–1.0; p=0.07). The proportions reaching 50% improvement in pain were 45%,
41%, and 41% respectively; there was a small, yet significant, impact of baseline severity (OR=1.04;
CI=1.03–1.05; p<0.0001) that did not meet criteria for clinical relevance. Both endpoints revealed
strong construct validity, and detected “minimally clinically important differences” (0.5 SD) in bowel
symptoms. Both endpoints provided better discriminant spread in IBS-D than IBS-C subgroups.
Conclusions—Both the traditional binary and 50% improvement endpoints are equivalent in their
psychometric properties. Neither is impacted by baseline severity, and both demonstrate excellent
construct validity. They are optimized for the IBS-D population, but also appear valid in IBS-C.
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BACKGROUND
There is debate about how best to measure patient reported outcomes (PROs) in irritable bowel
syndrome (IBS). This debate is important, because IBS remains a patient reported condition
that cannot yet be reliably diagnosed or monitored with biomarkers alone; patient reports are
essential. In the absence of valid and reliable biomarkers to accurately sub-stratify patients
within an otherwise heterogeneous condition, clinicians and investigators are left interpreting
patient reported symptoms to determine the diagnosis, gauge overall disease severity, develop
rational treatment plans, and assess outcomes.
This challenge is now front and center for clinicians, investigators, and regulatory agencies
such as the U.S. Food and Drug Administration. The charge for all stakeholders is to identify
one or more PRO measures that are sufficiently reliable and valid, both for clinical trials and
clinical practice. An optimal PRO measure must be easily administered, able to discriminate
between important patient sub-groups and disease states in a statistically significant and
clinically relevant manner, predictable in behavior when tracked with other indicators of illness
severity, not conditional on baseline severity, and readily interpretable.1
Most all of the recent high quality clinical trials in IBS employed a binary PRO endpoint, such
as “adequate relief,” “satisfactory relief,” or “considerable relief.”2 These endpoints have two
levels, and therefore provide a dichotomous stratification of responder status (yes/no relief).
Binary endpoints are useful because they are easy to administer and straightforward to interpret.
2, 3 Moreover, they have been retrospectively shown to have construct validity when compared
against other endpoints in IBS,4 and they have predicted effectiveness of medications and
improvement in quality of life measures.20 On this basis, recent systematic reviews of the
published evidence of IBS endpoints support the use of binary endpoints as standard for IBS
clinical trials.2, 3
However, binary endpoints have been criticized on several grounds. First, Whitehead and
colleagues observed that “satisfactory relief” of bowel symptoms – a type of binary endpoint
– appeared to be confounded by baseline IBS severity.5 The authors found that patients with
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severe IBS who received usual care in a health maintenance organization were less likely to
achieve a response over time compared to those with less severe IBS. In contrast, patients with
less severe IBS were most likely to achieve “satisfactory relief” over time, but revealed no
improvements in symptom severity. Although other investigators have not confirmed these
findings in different IBS populations exposed to either pharmacological or behavioral therapy
in clinical trials,6–8 the results from Whitehead et al. suggest that the performance of binary
endpoints might partly depend on baseline severity. In theory, a reliable PRO measure should
not be conditional on baseline severity. However, evaluation using the “adequate relief”
endpoint in a randomized, placebo controlled trial did not reveal responses to be sensitive to
patient baseline severity.2 Second, it has been argued that binary endpoints may not detect
minimally clinically important differences (MCIDs) in symptoms or health related quality of
life (HRQOL), and do not provide enough resolution to detect small changes in health status
over time. Third, it is claimed that the binary endpoints lack sufficient capacity to track key
illness domains or successfully discriminate between clinical sub-groups or disease states.
Finally, these endpoints were not derived from patient focus groups – the “gold standard”
approach for developing endpoints.1
The use of a multi-item symptom questionnaire is an alternative to binary endpoints.2 However,
only one IBS-specific symptom severity questionnaire has been shown to be responsive to
treatment effects: the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS).9, 10
Whitehead and colleagues have shown that the IBS-SSS is not conditional on baseline severity,
and proposed a “50% improvement” criterion for establishing a responder, in which patients
improving by at least 50% from their baseline severity score are considered to have clinically
improved.5 When using the 50% improvement criterion, Whitehead et al. found that response
to usual care was not dependent on baseline severity, and therefore proposed that the 50%
improvement definition may be superior to binary endpoints, e.g. “adequate relief” or
“satisfactory relief.”5
In light of this background, we performed a large pooled analysis of patient-level data from
existing clinical trials to evaluate and compare the psychometric properties of endpoints used
in IBS trials, including binary responses and 50% improvement in symptom severity. We
retrospectively tested the properties of these endpoints by pooling patient-level data from 12
trials including over 10,000 patients. The specific aims were to determine whether either type
of PRO endpoint is influenced by baseline IBS severity, and whether any of the responder
definitions can detect MCIDs in cardinal IBS bowel symptoms, patient reported visceral
sensitivity, disease-targeted HRQOL, psychological distress, and work productivity – all
components of the evolving model of IBS illness severity.11, 12
METHODS
Pooling Patient Level Data from Databases of IBS Clinical Trials
Prior to conducting psychometric analyses of IBS endpoints, we first sought to pool patient-
level data from available trials. This allowed the opportunity to maximize the robustness and
explanatory power of its findings, and to test whether those findings can be generalized across
data sets. The sections below describe the steps followed to systematically acquire, evaluate,
and harmonize data from existing clinical trials.
Data Acquisition—We identified pharmaceutical companies that have previously conducted
randomized, controlled clinical trials in IBS. We contacted each company, and provided
documentation describing the study objectives and proposed analyses. Six companies provided
evaluable patient-level trial data, including AstraZeneca (1 study), GlaxoSmithKline (2
studies), Ironwood (1 study), Novartis Pharmaceuticals (5 studies), and Solvay (3 studies).
Table 1 provides an overview of the data employed for this pooled analysis. There were 10,066
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subjects in the combined data set, of which 9,044 had minimum required data in order to be
eligible for inclusion in our analyses (i.e. baseline and follow-up bowel symptom scores, and
end-of-study or “last observation carried forward” [LOCF] binary response, as described
further below).
Initial Data Management and Mapping—We developed a list of content areas represented
in the included trials that would serve as the focus for data analysis. We then grouped the
content areas into major and minor domains, as displayed in Table 2. We created a single
harmonized extract data file that transformed the various data structures and variables into a
common format across each study. We retained both baseline and study endpoint variables for
the analyses. We relied on pre-calculated LOCF variables, when available, for patients unable
to complete the full study duration.
Standardizing of Variables—There are important challenges and potential barriers to
successfully harmonizing data from several studies. These include disparate binary outcome
measures (e.g., “satisfactory relief” vs. “adequate relief” vs. “considerable relief”), measures
of IBS severity (e.g. “pain severity” vs. IBS-SSS), and scales for all covariates (e.g., 5-point
vs. 7-point Likert scales). To allow for cross-trial analysis, we converted each of the continuous
variables to a common scale. This involved the following steps:
1. Within each study, calculation of the mean and standard deviation of each baseline
measure.
2. Use of these values to transform the variable to a standardized z-score (e.g., (z=x−μ)/
σ).
3. For ease of interpretation, re-centering of the distribution to a mean of 100 and a
standard deviation of 10 – a variation of the traditional T-scale (e.g., T=(z*10)+100).
4. Application of the same steps that were used to transform the baseline score to the
study endpoints and LOCF versions of the respective variables. By using the baseline
values, any absolute changes from baseline to end-of-study would be retained in the
scale transformation.
Calculation of “Minimum Clinically Important Difference” (MCID) Scores
For binary endpoints, responses of satisfactory relief, adequate relief, or considerable relief are
presumed to reflect clinically significant outcomes. Although some outcome measures have
empirically derived MCIDs (e.g., the MCID of the IBS-QOL is between 10 and14),13 most
linear endpoints have no established MCID benchmarks. In the absence of empiric MCID
definitions, one established technique recommended by Norman et al. is to assume that a half
standard deviation (SD) improvement (effect size of 0.5) equates with meaningful change.14
This approach is based on the “remarkable universality” of a half SD as a surrogate measure
for clinical importance, and correlates with a “medium” effect size using the traditional rules
of Cohen.15 The half SD technique has been used by previous investigators in IBS, including
the developers of the IBS-QOL instrument.13 The Norman approach allows for standardization
of a MCID definition across disparate measures, and thus serves as an “exchange currency” to
pool various outcome measures and covariates in the same analysis.
We also calculated MCIDs for all linear variables, and assigned end-of-study MCID status for
each domain in each patient. To do this, we first calculated a “baseline to study endpoint change
score” for each domain, using subjects with harmonized scale scores at both time points. We
evaluated whether the size of the change score exceeded one-half standard deviation which
was 5 given a standard deviation of 10 on the harmonized T-scale.14
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Construction of Binary Endpoint
A version of the binary endpoint was constructed for each subject using the result reported in
the original trial (e.g. “adequate relief”). Although the various included endpoints had different
wording, they all shared in common a binary response scale. For purposes of meta-analysis,
we assumed that patients understood a similar meaning from the various questions (e.g.
“adequate relief” vs. “considerable relief” [yes, no]) to allow harmonization across binary
endpoints. This assumption, although arguable, allows for construction of a large harmonized
database; meta-analysis inevitably requires the assumption that combined data are sufficiently
alike to allow for harmonization. If a subject was missing the end of study binary endpoint
data, we substituted the LOCF version of the measure. In this manner, we were able to include
patients who did not complete the full study but nonetheless contributed data in the form of an
LOCF data point.
Creation of a Harmonized Pain Severity Scale
Because all the studies included a measure of abdominal pain at baseline and follow-up, and
since pain is one of the cornerstones of “IBS severity,”11, 12 we adopted pain as our surrogate
for IBS illness severity. All studies provided data regarding abdominal pain, thus providing an
opportunity to create a harmonized “severity” scale based on pain. As with the other
harmonized T-scales, we created a harmonized pain severity score, with a mean of 100 and a
standard deviation of 10 (higher scores indicated higher severity).
Impact of Baseline Severity on Performance of Endpoints of Interest
We assessed the relationship between baseline severity and end-of-study response status using
two competing “responder” definitions: (1) harmonized binary response status; and (2) 50%
improvement in severity. We defined a “50% responder” as someone who reported at least a
50% reduction in IBS pain severity over time on the harmonized pain scale described above,
using the baseline severity score as the reference point.
Using the harmonized pain severity scale, we divided patients at baseline into three severity
levels, as defined by tertiles from the harmonized baseline severity T-scale (i.e., mild=bottom
tertile, moderate=middle tertile, severe=top tertile). We then measured end-of-study binary
response status stratified across the three severity groups to determine whether each endpoint
was influenced by baseline IBS severity.
To answer the question whether each endpoint has utility in assessing treatment response across
varying levels of baseline IBS symptom severity, we repeated the analyses within treatment
sub-groups, first limiting to treatment arms only, then to placebo arms, and then to all data
combined. For all analyses, we compared response status across tertiles using chi-squared, and
adopted a p-value <0.05 as our definition of statistical significance.
Consideration of Clinical Relevance
Because the sample size is large, we anticipated that some differences might be statistically
significant but not clinically relevant. To estimate the clinical relevance of differences across
responder groups, we performed a separate set of analyses for each responder definition in
which we measured mean baseline severity in responder vs. non-responder groups using T-
tests. Because the MCID on the harmonized severity scale was set at 5, any difference between
groups less than 5 indicated sub-MCID differences and was deemed to be of small to non-
existent clinical significance. For between-group differences in subjects receiving
investigational treatment, the MCID was assessed for significance using the rules of Cohen.16
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We performed a series of multivariable logistic regression models to measure the independent
effect of baseline IBS severity on end-of-study response status for each of the three response
definitions. These models adjusted for IBS sub-type, treatment status, age, sex, and disease
duration.
Prospective Analysis of Construct Validity of Endpoints of Interest
We performed a series of prospective construct validity analyses to measure the performance
of the competing responder definitions. For these analyses we measured the ability of each
responder definition to track with several clinically important IBS constructs, including the
cardinal bowel symptoms (abdominal pain, bloating, stool frequency, stool form, urgency,
incomplete evacuation, straining), patient reported visceral sensitivity (using the visceral
sensitivity index [VSI], a 15-item scale that is a reliable and valid measure of gastrointestinal
symptom-specific anxiety17), HRQOL, and work productivity.
For each responder definition (e.g. binary endpoint or 50% improvement), we assessed
construct validity by conducting a series of T-tests to compare change scores in each construct
stratified by response status. We calculated the p-value for each comparison (responder vs.
non-responder), adopting <0.05 as evidence for statistical significance. However, due to the
large sample size, we also adopted a measure of clinical relevance, that is achievement of an
MCID using the 0.5 SD definition.14 For this set of analyses, we calculated the proportion of
patients achieving an MCID over time for each construct stratified by response status. Because
the results might vary by IBS sub-type, we repeated the analyses in IBS-C and IBS-D sub-
groups, and report the results both in combination and separately.
RESULTS
Patient Characteristics
There were 9044 evaluable subjects in the 12 trials. The mean age was 44.3 years and 85%
were female. More than half of the sample had IBS-C (58%), and 31% IBS-D. Fifty-three
percent of the cohort had received an investigational IBS treatment, whereas the rest received
placebo. Using the binary response definition, 60% of the overall cohort achieved a response
at the end of the study follow-up period. Table 3 displays the key descriptive statistics of
patients included in the sample.
Effect of Baseline Severity on Responder Status for the Binary Responses
There were 8457 subjects with data included in the analyses with data comparing binary
response status with baseline severity. Figure 1 portrays the percentage of patients responding,
using the binary definition, stratified by baseline severity tertiles. The data are provided for
three groups: all subjects combined, subjects receiving investigational treatment, and subjects
receiving placebo.
The proportion achieving a response in the mild, moderate, and severe groups was 42%, 40%,
and 38%, respectively. Because of the large sample size, these differences were highly
significant for both the overall group (p=0.0008) and placebo sub-group (p=0.009), but not for
the investigational treatment group (p=0.36) using a chi-square test. However, multivariable
analysis using data from both groups and adjusting for age, IBS sub-type, sex, disease duration
and baseline pain as a continuous variable (N=5510 for model), found a non-significant
relationship between baseline pain severity and response status (OR=0.995; 95% CI=0.99–1;
p=0.07).
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Table 4 provides the results of the T-test comparing mean baseline severity scores in patients
with vs. without end-of-study (or LOCF) binary response, stratified by treatment status. The
data reveal that the absolute differences in baseline severity by binary status were small for
each group. For example, the absolute difference in the combined group was 0.6 points, which
is below the a priori MCID of 5 points, and indicating that the differences were not clinically
significant for any of the sub-groups.
Effect of Baseline Severity on Responder Status 50% Improvement Responder Status
There were 7487 subjects with data comparing 50% improvement in pain severity response
status with baseline severity. Figure 2 portrays the percentage of patients responding, using
the 50% improvement definition, stratified by baseline severity tertiles. The proportion
achieving 50% improvement in the mild, moderate, and severe groups was 45%, 41%, and
41%, respectively. The chi-squared p-value was highly significant for both the overall group
and placebo groups (p=0.002 for both), but not for the treatment group (p=0.27). In
multivariable logistic regression analysis with baseline pain as a continuous predictor and
adjusting for potential confounders, the relationship between baseline severity and 50%
improvement status was statistically significant (OR=1.04; 95% CI=1.033–1.047; p<0.0001).
Although baseline severity independently predicted end-of-study 50% improvement in
severity, the relationship was numerically small. To test for clinical relevancy, we performed
a T-test comparing mean baseline severity scores in patients with vs. without 50%
improvement, stratified by treatment status (Table 4). The absolute differences in baseline
severity by 50% improvement status were small for each group. For example, the absolute
difference in the combined group was 0.7 points which is below the a priori MCID of 5 points,
and indicates that the differences were not clinically significant for any of the sub-groups. The
between-group difference (i.e. patients with vs. without 50% improvement) among subjects
receiving investigational treatment was 2.1 points, or an effect size of 0.21 – also below an
MCID using the rules of Cohen.16
Prospective Construct Validity of Binary Response and 50% Improvement—The
prospective construct validity of the binary endpoint was first tested by performing a series of
T-tests to compare mean difference in difference (DID) scores for each symptom or construct
in Table 2, stratified by binary response status. The full results of the 23 T-tests are presented
in the Appendix. All of the T-tests yielded p values <0.0005, indicating that the binary response
endpoint was able to discriminate between groups for all 23 tested constructs. Using the 50%
improvement endpoint, the same analysis found all T-tests yielded p values <0.007. Therefore,
both the binary and 50% improvement endpoints were able to discriminate between groups for
all tested constructs.
To measure the clinical relevance of these results, we overlaid a 0.5 SD benchmark for each
T-test, as described in the methods. Figure 3 portrays the absolute difference in difference
across all 23 constructs, placing the results of the two endpoints side-by-side. The dashed line
marked the threshold for clinical relevancy. Visual inspection of Figure 3 reveals that both
endpoints performed almost equivalently in terms of achieving clinically relevant separation
between groups. The largest difference in difference scores were achieved in separating patients
by abdominal bloating and pain, with the 50% improvement definition achieving numerically
higher discriminant validity than the binary response definition. Both endpoints achieved
clinically relevant differences for stool consistency, urgency, hard stool, overall HRQOL, body
image, fatigue, VSI scores, presenteeism, and overall work productivity. In contrast, neither
endpoint clinically separated groups by stool frequency, incomplete evacuation, straining,
activity interference, diet, relationships, sexual function, social function, sleep, or absenteeism.
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In addition, we also measured clinical relevancy by calculating the proportion of patients in
each group achieving an MCID, using the 0.5 SD metric for each variable. Figure 4A portrays
the results in IBS-C group. In this group, both endpoints provided maximal discriminant ability
for bloating, with lower discriminant ability of both endpoints for all other symptoms in the
IBS-C group, with the smallest values in the stool frequency comparisons. Compared to the
binary response endpoint, the 50% improvement definition achieved a higher numerical spread
between groups for bloating, urgency, hard stool, incomplete evacuation, and straining. In
contrast, the binary response endpoint achieved slightly improved discriminant ability for stool
frequency and consistency.
Figure 4B portrays the results in IBS-D group. The data reveal that both endpoints provided
maximal discriminant ability for bloating and urgency. Unlike in the IBS-C subgroup, the
discriminant ability of both endpoints remained sizeable (20% spread or higher) for all
symptoms except straining, which itself is not a cardinal symptom of IBS-D, and therefore of
unclear significance in this patient subgroup.
DISCUSSION
This pooled analysis was motivated by questions regarding the validity of traditional IBS
endpoints, with particular focus on binary endpoints.5 The Rome Foundation Outcomes and
Endpoints Committee combined data from over 9000 patients from 12 randomized controlled
drug trials involving 5 separate investigational treatments with different mechanisms of action.
Our goal was to leverage the power of this harmonized database to explicitly test key
psychometric properties of binary endpoints, and to compare the performance of binary
endpoint with the “50% improvement” criterion suggested as an alternative metric.5
Regarding the impact of baseline severity on endpoint performance, we found that the
relationship between severity and binary responder status was not statistically significant in
the adjusted analysis, and the relationship did not meet criteria for clinical significance,
regardless of the resulting p-values. In contrast, we found that the “50% improvement” criterion
for pain severity was significantly associated with baseline severity in the adjusted analysis,
particularly for patients receiving investigational treatment. However, the clinical relevance
of the relationship with baseline severity was minimal across all treatment groups. The
observation that there is not an important relationship between baseline pain severity and
response status, either defined with a binary endpoint or “50% improvement” criterion, is
consistent with previous studies6–8 and contrary to the results of Whitehead et al.5 It is possible
that the analyses reported in a community sample by Whitehead et al. included subjects from
a health maintenance organization with a broader range of IBS symptom severity than the
subjects included in the clinical trials summarized in this pooled analysis.
We further tested the construct validity of both endpoints against a range of IBS illness
domains. In short, we found that both the binary response and 50% improvement endpoints
reveal excellent construct validity across a wide range of variables (Figure 3). Both endpoints
are able to detect MCIDs in key bowel symptoms, including bloating, abdominal pain,
consistency, urgency, and hard stool. They are also able to detect MCIDs in worker
productivity, visceral hypersensitivity scores, and fatigue scores. Whereas both endpoints are
able to detect MCIDs for overall HRQOL, they are less capable of detecting MCIDs for the
individual HRQOL components. Thus, both endpoints track with key components of IBS
illness severity, neither is clearly superior over the other, and both work as expected.
We found that both the binary response and 50% improvement endpoints performed similarly
in discriminating between MCID responders and non-responders for bowel symptoms in IBS
sub-groups. Of note, both endpoints appear to provide better discrimination in the IBS-D than
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IBS-C subgroups (Figures 4A and 4B). This has potential implications for studies that seek to
establish differences in response rates between treatment and placebo groups. The data suggest
that both endpoints may be better suited for the IBS-D population. In IBS-C patients, the
percentage achieving an MCID is numerically smaller, suggesting that more sensitive
endpoints might be necessary for the IBS-C groups. A corollary is that drugs failing to show
large effect sizes in this population might have been hampered by the psychometric properties
of the binary endpoints. Further research should aim to test current and future endpoints in both
IBS-C and IBS-D subgroups, and to establish whether the psychometric properties are similar
or different in these phenotypically distinct populations. It is possible that a “one size fits all”
approach to endpoints may not apply in IBS: different sub-groups may be better captured with
tailored endpoints. This finding raises the question of whether clinical trialists should employ
different endpoints for IBS-C vs. IBS-D. This would represent a notable change in our approach
to endpoint measurement in IBS. Our study is unable to determine why endpoints may behave
differently by sub-group; instead it merely raises the question. Future research should aim to
understand why this might be. In the meantime, our finding suggests that further research
should carefully evaluate endpoint performance in both groups separately.
These data add to previous conclusions that global binary endpoints are useful in IBS,2 based
on the collective clinical trial experience in almost 20,000 IBS patients with at least five
different medications (alosetron, cilansetron, tegaserod, lubiprostone, dextofisopam) tested
with binary endpoints. Binary endpoints have been devalued given the relative lack of
psychometric validation until now. Yet even before this pooled analysis, previous investigators
demonstrated that binary endpoints were acceptable to patients, and that binary responses were
driven by the patients’ most bothersome symptom.18, 19 Based on a systematic review of 12
pre-specified criteria, Bijkerk et al. concluded that the weight of evidence was in favor of using
“adequate relief” – a binary endpoint – among the different available endpoints used in IBS
trials.3 Drugs that are effective, based on the binary response endpoints, were also found to
improve general or disease-specific quality of life.20 Based on these collective data, the Rome
III guidance on IBS clinical trials endorsed using a global measure that integrates the symptom
data into a single numerical index, measured either as a binary endpoint or a continuous
integrative symptom questionnaire such as the IBS-SSS.10 We have now expanded and
confirmed these collective results and conclusions by demonstrating excellent construct
validity of the binary endpoints with a wide range of patient symptoms, psychosocial illness
experiences, visceral sensitivity reporting, HRQOL, and even work productivity. Moreover,
we have found that the performance of a binary endpoint is psychometrically equivalent to
monitoring pain severity on a continuous scale, and adopting the “50% improvement” criterion
recommended by Whitehead et al.5
Based on our data, coupled with extensive pre-existing data supporting the validity of the binary
endpoints, it is reasonable to conclude that use of binary endpoints in IBS clinical trials is
rational and valid. No endpoint can be fully validated; establishing the validity of a PRO is an
ongoing and iterative effort. But our results add to this effort and further confirm that binary
endpoints get the job done – they work as expected. This is an important conclusion because
it supports the validity of existing studies, highlights the efficacy of therapies originally tested
in trials employing binary endpoints, and indicates that future studies could also use these
endpoints without undue concern.
Our study has several strengths. First, the sample size of this analysis is large, and the use of
pooled patient-level data is a more powerful method of synthesizing multiple studies than
conventional meta-analysis. This provides considerable power to investigate the psychometric
properties of IBS endpoints. Second, because we are cognizant that large sample sizes can yield
statistically significant relationships that are not clinically relevant, we overlaid a priori criteria
for clinical relevance, and reported results that were both statistically significant and clinically
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relevant. Third, we conducted sub-analyses across key groups, including IBS sub-groups
(i.e. IBS-C vs. IBS-D) and treatment groups (active vs. placebo). This allows us to generalize
our results across different populations. Finally, we measured a range of key psychometric
properties using multiple clinical anchors. This allows us to triangulate the validity of the
endpoints from several perspectives.
Our study has limitations. First, as with any meta-analysis, we were faced with combining
disparate data from different studies, each with unique inclusion and exclusion criteria, disease
characteristics, and endpoint evaluations. However, we have been careful to acknowledge these
variations, as described in our methods section, and have attempted to balance the power of
harmonizing large datasets with the inevitable methodological shortcomings of combining
disparate data. Second, it is possible that patients in randomized controlled trials are
systematically different from other populations of IBS patients. However, this is precisely the
population in question, since the current main use of PRO measures is for clinical trials to test
the effect of pharmacologic interventions in IBS. As PROs continue to penetrate into everyday
clinical practice, further validation studies will be necessary in non-clinical trial populations.
Third, our measure of “IBS severity” was limited to “pain severity.” We were unable to employ
multi-attribute severity scales like the IBS-SSS, because there were inadequate data for this
purpose. However, pain is a cardinal symptom of IBS,11, 12 and it drives overall illness severity
more, on average, than any other symptom. In short, there is sufficient rationale and precedent
to use pain severity as a surrogate for overall IBS illness severity, as we have done here.
In conclusion, this large patient-level meta-analysis reveals that both the binary and 50%
improvement endpoints are equivalent in their psychometric properties. Neither is impacted
by baseline severity, and both demonstrate excellent construct validity. They appear optimized
for the IBS-D population, but are also valid in IBS-C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HRQOL health related quality of life
IBS irritable bowel syndrome
IBS-SSS IBS severity symptom score
LOCF last observation carried forward
MCID minimal clinically important difference
OR odds ratio
PRO patient resported outcome
VSI visceral sensitivity index
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Relationship Between Trichotomized Baseline Severity and Responder Status, Defined using
Harmonized Binary Endpoint (aka “Adequate Relief”). Data are provided for the overall,
treatment, and placebo groups.
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Relationship Between Trichotomized Baseline Severity and Responder Status, Defined using
50% Improvement from Baseline Severity. Data are provided for the overall, treatment, and
placebo groups.
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“Difference in Difference” (DID) Scores Stratified by Response Status. The Figure depicts two
series of data: one for adequate relief (AR), and one for 50% improvement in severity. The
data are stratified by 23 variables, including bowel symptoms, HRQOL domains, and work
productivity domains. Each bar reveals the mean DID scores for each variable between
responders and non-responders, stratified by responder definition. The higher the DID the
better the discriminant validity. For example, using the AR response definition, the mean DID
abdominal pain score between responder groups was 15. In contrast, using the 50%
improvement definition, the mean DID score between groups was 22.5. Both bars exceed the
threshold for “clinical significance” depicted by the dashed line at 5-points (i.e. half standard
deviation MCID definition).
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Proportion of Patients Achieving an MCID for Individual Bowel Symptoms – AR vs. 50%.
Panel A provides data in the IBS-C sub-population, and Panel B provides data in the IBD-D
sub-population. Each bar represents the results of an individual 2×2 table, and depicts the
difference in MCID achievement between responders and non-responders. For example, 38%
more IBS-C patients in the binary response group achieved an MCID in bloating vs. those not
achieving a binary response. In contrast, 52% more IBS-C patients in the 50% improvement
group achieved an MCID in bloating vs. those not achieving 50% improvement.
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Table 2
Variables Included in Datasets, Grouped by Major and Minor Domains. The scaling and instrumentation for each
minor domain varied considerably from study to study. Refer to the text for the method of harmonization across
studies.
































Binary Outcomes Global adequate relief
Pain relief
Global Improvement Continuous global improvement
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Table 3
Subject Descriptive Statistics from Harmonized Patient-Level Dataset of IBS Clinical Trials
Variable Aggregate Mean N
Gender (% Female) 84.8% 9044
Age (years) 44.3 ±12.7 9044
Duration of IBS (years) 11.3 ±11 6090
IBS Sub-Groups




 % Receiving Treatment 53.4% 9044
 % Receiving Placebo 46.6%
Trichotomized Baseline Severity
 % Mild (bottom tertile) 34.5% 8457
 % Moderate (middle tertile) 33.5%
 % Severe (top tertile) 31.9%
End-of-Study Responder Status
 % Responder 59.8% 9044
 % Non-Responder 40.2%
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Table 4
T-Test Comparing Baseline Severity between responders vs. non-responders. The top panel provides data
stratified by the harmonized binary response endpoint, and the lower panel provides data stratified by 50%
improvement in symptom severity. See text for details.
Binary Responder Data
Mean Severity Score (±SD) in
Responders
Mean Severity Score (±SD) in Non-
Responders P-Value for T-Test
Treatment and Placebo Groups Combined 99.6 ±10 100.2 ±9.9 0.01
Treatment Group Alone 99.8 ±9.9 100.2 ±10.0 0.70
Placebo Group Alone 99.2 ±10.2 100.2 ±9.9 0.01
50% Improvement in Symptom Severity
Treatment and Placebo Groups Combined 99.5 ±10.1 100.2 ±9.7 0.03
Treatment Group Alone 99.4 ±10.1 97.3 ±10.0 <0.001
Placebo Group Alone 99.8 ±9.9 100.1 ±9.8 0.24
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